Drug Profile
Interleukin-6 - Ajinomoto
Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Ajinomoto
- Class Antineoplastics; Interleukins
- Mechanism of Action Immunomodulators; Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Thrombocytopenia
Most Recent Events
- 27 Apr 1998 Discontinued-II for Cancer in Japan (Unknown route)
- 27 Apr 1998 Discontinued-II for Thrombocytopenia in Japan (Unknown route)
- 23 Jul 1997 Phase-II clinical trials for Cancer in Japan (Unknown route)